REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2021

Nov 3, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENERON PHARMACEUTICALS, INC. (REGN)
CIK: 0000872589
Period of Report: 2021-11-01

Reporting Person: McCourt Marion (EVP Commercial)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-11-01	Common Stock	M	1000	$342.93	Acquired	18038	Direct
2021-11-01	Common Stock	S	1000	$640.0	Disposed	17038	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-11-01	Non-Qualified Stock Option (right to buy)	$342.93	M	1000	Disposed	2028-02-12	Common Stock (1000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	116	Indirect

Footnotes

F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F2: The stock option award vests in four equal annual installments, commencing one year after the date of grant.